Noah J. Marcus

Noah J. Marcus

Auto-generated profile, based on publicly available information

Noah J. Marcus

Department of Physiology and Pharmacology, Des Moines University Medicine and Health Sciences, Des Moines, IA, United States

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in JACC
Verified
Journal Article
Closed access
Rodrigo Del RioRodrigo Del Rio
Rodrigo Del Rio
NMNoah J. Marcus
Noah J. Marcus
HSHarold D. Schultz
Harold D. Schultz

14 January 2014 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
NMNoah J. Marcus
Noah J. Marcus
Rodrigo Del RioRodrigo Del Rio
Rodrigo Del Rio
ESEvan P. Schultz
Evan P. Schultz
XXXiao‐Hong Xia
Xiao‐Hong Xia
HSHarold D. Schultz
Harold D. Schultz

1 April 2010 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
NMNoah J. Marcus
Noah J. Marcus
YLYu-Long Li
Yu-Long Li
CBCynthia E. Bird
Cynthia E. Bird
HSHarold D. Schultz
Harold D. Schultz
BMBarbara J. Morgan
Barbara J. Morgan

3 December 2019 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
Hugo S. DiazHugo S. Diaz
Hugo S. Diaz
CTCamilo Toledo
Camilo Toledo
DADavid Cristobal Andrade
David Cristobal Andrade
NMNoah J. Marcus
Noah J. Marcus
Rodrigo Del RioRodrigo Del Rio
Rodrigo Del Rio

15 January 2015 in Experimental Physiology
Verified
Journal Article
Open access
PDF file
HSHarold D. Schultz
Harold D. Schultz
NMNoah J. Marcus
Noah J. Marcus
Rodrigo Del RioRodrigo Del Rio
Rodrigo Del Rio
New Findings: What is the topic of this review? Carotid body chemoreceptor activity is tonically elevated in heart failure and contributes to morbidity due to the reflex activation of sympathetic nerve activity and destabilization of breathing. The potential causes for the enhanced chemoreceptor activation in heart failure are discussed. What advances does it highlight? The role of a chronic reduction in blood flow to the carotid body due to cardiac failure and its impact on signalling pathways in the carotid body is discussed. Recent advances have attracted interest in the potential for carotid body (CB) ablation or desensitization as an effective strategy for clinical treatment and management of cardiorespiratory diseases, including hypertension, heart failure, diabetes mellitus, metabolic syndrome and renal failure. These disease states have in common sympathetic overactivity, which plays an important role in the development and progression of the disease and is often associated with breathing dysregulation, which in turn is likely to mediate or aggravate the autonomic imbalance. Evidence from both chronic heart failure (CHF) patients and animal models indicates that the CB chemoreflex is enhanced in CHF and contributes to the tonic elevation in sympathetic activity and the development of periodic breathing associated with the disease. Although this maladaptive change is likely to derive from altered function at all levels of the reflex arc, a tonic increase in afferent activity from CB glomus cells is likely to be a main driving force. This report focuses on our understanding of mechanisms that alter CB function in CHF and their potential translational impact on treatment of CHF.

4 July 2013 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
HSHarold D. Schultz
Harold D. Schultz
NMNoah J. Marcus
Noah J. Marcus
Rodrigo Del RioRodrigo Del Rio
Rodrigo Del Rio